pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Orenitram
drug
save

treprostinil diolamine ER

Marketedupdated 3mo ago
by $UTHR UNITED THERAPEUTICS Corp
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 18, 2026
61 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (35)

  • Aug 11, 2031formulationUS 87478975.0y
  • Aug 11, 2031formulationUS 87478975.0y
  • Aug 11, 2031formulationUS 87478975.0y
  • Aug 11, 2031formulationUS 87478975.0y
  • Aug 11, 2031formulationUS 87478975.0y
  • Jan 22, 2031formulationUS 83498924.4y
  • Jan 22, 2031formulationUS 83498924.4y
  • Jan 22, 2031formulationUS 83498924.4y
  • Jan 22, 2031formulationUS 83498924.4y
  • Jan 22, 2031formulationUS 83498924.4y
  • Feb 13, 2030formulationUS 84101693.5y
  • Feb 13, 2030formulationUS 84101693.5y
  • Feb 13, 2030formulationUS 84101693.5y
  • Feb 13, 2030formulationUS 84101693.5y
  • Feb 13, 2030formulationUS 84101693.5y
  • Dec 15, 2028compositionUS 117238872.3y
  • Dec 15, 2028compositionUS 117238872.3y
  • Dec 15, 2028compositionUS 117238872.3y
  • Dec 15, 2028compositionUS 117238872.3y
  • Dec 15, 2028compositionUS 117238872.3y
  • Dec 15, 2028compositionUS 95930662.3y
  • Dec 15, 2028compositionUS 95930662.3y
  • Dec 15, 2028compositionUS 95930662.3y
  • Dec 15, 2028compositionUS 95930662.3y
  • Dec 15, 2028compositionUS 95930662.3y
  • Jul 30, 2026compositionUS 7417070
  • Jul 30, 2026compositionUS 7417070
  • Jul 30, 2026compositionUS 7417070
  • Jul 30, 2026compositionUS 7417070
  • Jul 30, 2026compositionUS 7417070
  • Apr 27, 2026formulationUS 9393203
  • Apr 27, 2026formulationUS 9393203
  • Apr 27, 2026formulationUS 9393203
  • Apr 27, 2026formulationUS 9393203
  • Apr 27, 2026formulationUS 9393203

FDA exclusivities (5)

  • Oct 18, 2026ODE-272Orphan Drug (7y)61d
  • Oct 18, 2026ODE-272Orphan Drug (7y)61d
  • Oct 18, 2026ODE-272Orphan Drug (7y)61d
  • Oct 18, 2026ODE-272Orphan Drug (7y)61d
  • Oct 18, 2026ODE-272Orphan Drug (7y)61d

News(0)

no news has mentioned this drug yet

brand
Orenitram
generic
treprostinil diolamine
indication
Pulmonary Arterial Hypertension
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 10m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?